克立硼罗逆转轻中度特应性皮炎蛋白质组失调
这项2a期、单中心、患者内、溶媒对照研究对40例轻中度特应性皮炎成人及20名健康受试者进行蛋白质组分析,病灶随机双盲接受2%克立硼罗软膏或溶媒每日两次共14天。与溶媒相比,克立硼罗显著逆转病灶整体蛋白质组及Th2、Th17/Th22、T细胞活化等关键标志和通路的失调,向非病灶和正常皮肤靠近,并观察到与痛觉及Th2、Th17、中性粒细胞活化标志的显著临床相关性。
要点
- 克立硼罗显著逆转病灶蛋白质组失调,向非病灶和正常皮肤靠近。
- 显著临床相关见于痛觉及Th2、Th17、中性粒细胞活化相关标志。
- 结果支持局部PDE4抑制用于轻中度特应性皮炎治疗。
核心结论
- 克立硼罗诱导特应性皮炎蛋白质组向非病灶分子表型正常化,进一步支持局部PDE4抑制治疗轻中度特应性皮炎。
研究设计与样本
- 2a期、单中心、患者内、溶媒对照研究,纳入40例轻中度特应性皮炎成人和20名健康受试者。
- 特应性皮炎队列内2处目标病灶按1:1患者内随机双盲接受克立硼罗或溶媒每日两次共14天。
- 所有参与者在基线、仅特应性皮炎患者在可选第8天和第15天采集钻孔活检标本用于生物标志分析。
主要发现
- 与溶媒相比,克立硼罗显著逆转病灶整体蛋白质组及与特应性皮炎发病相关的关键标志和通路(如Th2、Th17/Th22和T细胞活化)的失调,向非病灶和正常皮肤靠近。
- 观察到与痛觉以及Th2、Th17和中性粒细胞活化相关标志的显著临床相关性。
临床怎么用
- 原文结论认为结果支持局部PDE4抑制用于轻中度特应性皮炎的治疗。
局限性
- 研究局限包括队列以白人患者为主、治疗时间相对较短以及克立硼罗按固定方案给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Safe and effective long-term topical treatments for atopic dermatitis (AD) remain limited. OBJECTIVE: In this phase 2a, single-center, intrapatient, and vehicle-controlled study, we examine the mechanism of action of crisaborole 2% ointment, a topical nonsteroidal PDE4 (phosphodiesterase-4) inhibitor, in a proteomic analysis of 40 adults with mild to moderate AD and 20 healthy subjects. METHODS: Within the AD cohort, 2 target lesions were randomized in an intrapatient (1:1) manner to double-blind crisaborole/vehicle applied twice daily for 14 days. Punch biopsy specimens were collected for biomarker analysis at baseline from all participants, then from AD patients only at day 8 (optional) and day 15. RESULTS: Compared to the vehicle, crisaborole significantly reversed dysregulation of the overall lesional proteome and of key markers and pathways (eg, Th2, Th17/Th22, and T-cell activation) associated with AD pathogenesis toward both nonlesional and normal skin. Significant clinical correlations were observed with markers associated with nociception and Th2, Th17, and neutrophilic activation. LIMITATIONS: Study limitations include predominance of white patients in the cohort, relatively short treatment time, and regimented administration of crisaborole. CONCLUSION: Our results demonstrate crisaborole-induced normalization of the AD proteome toward a nonlesional molecular phenotype and further support topical PDE4 inhibition in the treatment of mild to moderate AD.
引用
- Kim M, Del Duca E, Cheng J, et al. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin. J Am Acad Dermatol. 2023. PMID: 37054814. doi:10.1016/j.jaad.2023.02.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。